Research & Development

R&D Key Investments Highlights

Disruptive technology

Broad-range direct MDx’ technology has the potential for a significant game change to save billions of dollars healthcare costs worldwide, only accounting for the sepsis market.

Diagnosis with only one protocol

Sepsi MDx’ unique technology allows to test for multiple diseases besides sepsis and numerous pathogens using only one test and saving time, resources and money”.

Quality leader with pure reagents

Molzym’s reagents are ultra-pure significantly improving accuracy of molecular test results and appreciated by laboratories all over the globe.

Strong recurring revenues through own devices

Molzym`s automated microbial DNA isolation devices drive sales of associated testing kits and consumables.

Strong financial profile with break-even reached

Sepsi MDx’ unique technology allows to test for multiple diseases besides sepsis and numerous pathogens using only one test and saving time, resources and money”.

2020 © Gradian Diagnostics. All rights reserved